Fibrogen Inc (FGEN) 26.46 $FGEN
Week Ahead: Is GoDaddy The Master Of Its Domains? Up To 4 IPOs This Week
Renaissance Capital IPO Research - Seeking Alpha - Mon Mar 30, 6:26AM CDT
The IPO market should end the first quarter with a bang as GoDaddy (Pending: GDDY ) goes public during the shortened holiday week. GoDaddy to go public GoDaddy aims to raise $396 million at a market cap of $3 billion, or an enterprise value of...
WOWO: 8.41 (-0.88), KRNT: 14.99 (unch), VIRT: 21.81 (-0.54), TANH: 11.82 (+0.40), PRTY: 20.65 (-0.22), VRAY: (), VLRX: (), ATRA: 63.79 (+7.64), FGEN: 26.46 (-1.37), GDDY: 24.77 (-0.01)
FibroGen reports FY'14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:31PM CDT
FGEN: 26.46 (-1.37)
FibroGen Announces 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Mar 26, 3:01PM CDT
FibroGen, Inc. (Nasdaq: FGEN), a research-based biopharmaceutical company, today provided a corporate update and reported financial results for the year-ended December 31, 2014.
FGEN: 26.46 (-1.37)
FibroGen to Report Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015
Business Wire - Thu Mar 19, 3:01PM CDT
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
FGEN: 26.46 (-1.37)
5 Stocks Poised for Breakouts: Trevena, Inventergy and More
at The Street - Fri Mar 06, 6:00AM CST
These stocks look ready to break out and trade higher from current levels.
TRVN: 6.91 (-0.53), AMTX: 4.40 (+0.04), INVT: 0.36 (+0.02), JMEI: 22.24 (+0.37), FGEN: 26.46 (-1.37)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 423.57 (+1.46), PSTI: 2.80 (-0.03), ASPX: 100.79 (+0.09), LPTN: 2.26 (unch), IBIO: 0.95 (+0.04), FGEN: 26.46 (-1.37), AQXP: 7.91 (-0.41), GALT: 3.29 (+0.01), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), GILD: 104.18 (-1.02), CGEN: 7.10 (+0.01), FPRX: 24.07 (-0.85), CELGZ: 2.87 (+0.04)
Boehringer Ingelheim's OFEV cleared in Europe for IPF
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:26PM CST
AZN: 73.35 (+0.65), FGEN: 26.46 (-1.37), BMY: 66.60 (-0.21)
Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), ICPT: 280.45 (-8.26), FGEN: 26.46 (-1.37)
IPO Stock Watch: FibroGen Up With Liver-Disease Field
at Investor's Business Daily - Mon Jan 05, 3:40PM CST
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT)...
RPTP: 10.56 (-0.17), CNAT: 6.31 (-0.15), ICPT: 280.45 (-8.26), FGEN: 26.46 (-1.37)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 8.00 (-0.27), FGEN: 26.46 (-1.37), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
FibroGen: For One Of The More Promising Biotechs, A New Chance To Buy In
Don Dion - at Seeking Alpha - Tue Dec 09, 1:09PM CST
FGEN: 26.46 (-1.37)
What Are Your Stocks Really Worth?
Interactive Brokers - Seeking Alpha - Fri Dec 05, 3:00AM CST
The stock market by definition is the meeting place of willing buyers and sellers. But when you made a stock purchase, did you ever stop and think about who was on the other side of the trade? Chances are that a short seller provided liquidity rather...
KNDI: 12.22 (+0.11), INO: 10.39 (-0.09), GPRO: 46.25 (+1.94), GDP: 3.58 (-0.10), XONE: 14.83 (-0.14), CHKR: 8.14 (-0.07), LOCO: 28.22 (-0.34), FGEN: 26.46 (-1.37), DGLY: 13.13 (+0.08), PFL: 11.43 (+0.01)
FibroGen, Inc. Announces Full Exercise of Greenshoe Option
Business Wire - Mon Nov 17, 6:05AM CST
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price of $18.00 per share, less the underwriting discount. With this exercise, the initial public offering totals 9,315,000 shares of common stock of FibroGen, representing gross proceeds of approximately $167.7 million, prior to deducting the underwriting discount and estimated offering expenses.
FGEN: 26.46 (-1.37)
FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST
IPF: 22.43 (+0.06), AZN: 73.35 (+0.65), FGEN: 26.46 (-1.37)
IPO Preview: FibroGen
IPOdesktop - at Seeking Alpha - Fri Nov 14, 11:14AM CST
Based in San Francisco, CA, FibroGen (NASDAQ: FGEN ) scheduled a $124 million IPO on Nasdaq with a market capitalization of $975 million at a price range midpoint of $17.50 for Friday, Nov. 14, 2014. The full IPO calendar is available at ...
FGEN: 26.46 (-1.37)
FibroGen sets IPO price
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:45AM CST
FGEN: 26.46 (-1.37)
FibroGen, Inc. Announces Pricing of Its Initial Public Offering
Business Wire - Thu Nov 13, 8:56PM CST
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announces the pricing of its initial public offering of 8,100,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the shares are being offered by FibroGen. FibroGen completed a 1-for-2.5 reverse stock split effective as of November 10, 2014. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "FGEN" on November 14, 2014. In addition, FibroGen has granted the underwriters a 30-day option to purchase up to an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price. The offering is expected to close on November 19, 2014, subject to customary closing conditions.
FGEN: 26.46 (-1.37)
IPO Calendar: Virgin America Among 10 IPOs This Week
at Investor's Business Daily - Mon Nov 10, 3:32PM CST
Airline company Virgin America is among 10 IPOs scheduled this week that look to raise $2.2 billion, with half coming from the health care sector. The largest initial public offering planned is Axalta Coating Systems (AXTA), which looks to raise...
VA: 30.99 (+1.01), NAP: 15.15 (-0.26), AXTA: 30.99 (-0.57), EHIC: 10.38 (+0.08), FGEN: 26.46 (-1.37), PRAH: 27.90 (+0.42), SXB: (), LMRK: 17.77 (+0.15), JYNT: 8.56 (+0.31), NDRM: 13.35 (-0.74)
FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST
IPO: 24.98 (+0.05), BIS: 30.54 (+0.15), BIB: 177.06 (-0.89), AZN: 73.35 (+0.65), IBB: 363.84 (-0.66), FGEN: 26.46 (-1.37)
Week Ahead: 10 U.S. IPOs Planned For The Week Of November 10 As The IPO Market Hits 250 With Virgin America
Renaissance Capital IPO Research - Seeking Alpha - Mon Nov 10, 10:18AM CST
10 deals are on the IPO calendar for the week of November 10, 2014. The two largest, auto paint maker Axalta Coating Systems and contract research organization PRA Health Sciences, are both LBOs. Representing 27% of 2014 deal flow (65 to date),...
VA: 30.99 (+1.01), NAP: 15.15 (-0.26), AXTA: 30.99 (-0.57), EHIC: 10.38 (+0.08), FGEN: 26.46 (-1.37), PRAH: 27.90 (+0.42), SXB: (), LMRK: 17.77 (+0.15), JYNT: 8.56 (+0.31), NDRM: 13.35 (-0.74)
Week Ahead: Is GoDaddy The Master Of Its Domains? Up To 4 IPOs This Week
Renaissance Capital IPO Research - Seeking Alpha - Mon Mar 30, 6:26AM CDT
The IPO market should end the first quarter with a bang as GoDaddy (Pending: GDDY ) goes public during the shortened holiday week. GoDaddy to go public GoDaddy aims to raise $396 million at a market cap of $3 billion, or an enterprise value of...
WOWO: 8.41 (-0.88), KRNT: 14.99 (unch), VIRT: 21.81 (-0.54), TANH: 11.82 (+0.40), PRTY: 20.65 (-0.22), VRAY: (), VLRX: (), ATRA: 63.79 (+7.64), FGEN: 26.46 (-1.37), GDDY: 24.77 (-0.01)
FibroGen reports FY'14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 3:31PM CDT
FGEN: 26.46 (-1.37)
FibroGen Announces 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Mar 26, 3:01PM CDT
FibroGen, Inc. (Nasdaq: FGEN), a research-based biopharmaceutical company, today provided a corporate update and reported financial results for the year-ended December 31, 2014.
FGEN: 26.46 (-1.37)
FibroGen to Report Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015
Business Wire - Thu Mar 19, 3:01PM CDT
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
FGEN: 26.46 (-1.37)
5 Stocks Poised for Breakouts: Trevena, Inventergy and More
at The Street - Fri Mar 06, 6:00AM CST
These stocks look ready to break out and trade higher from current levels.
TRVN: 6.91 (-0.53), AMTX: 4.40 (+0.04), INVT: 0.36 (+0.02), JMEI: 22.24 (+0.37), FGEN: 26.46 (-1.37)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 423.57 (+1.46), PSTI: 2.80 (-0.03), ASPX: 100.79 (+0.09), LPTN: 2.26 (unch), IBIO: 0.95 (+0.04), FGEN: 26.46 (-1.37), AQXP: 7.91 (-0.41), GALT: 3.29 (+0.01), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), GSK: 46.57 (-0.67), GILD: 104.18 (-1.02), CGEN: 7.10 (+0.01), FPRX: 24.07 (-0.85), CELGZ: 2.87 (+0.04)
Boehringer Ingelheim's OFEV cleared in Europe for IPF
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:26PM CST
AZN: 73.35 (+0.65), FGEN: 26.46 (-1.37), BMY: 66.60 (-0.21)
Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 10.56 (-0.17), GILD: 104.18 (-1.02), CNAT: 6.31 (-0.15), ICPT: 280.45 (-8.26), FGEN: 26.46 (-1.37)
IPO Stock Watch: FibroGen Up With Liver-Disease Field
at Investor's Business Daily - Mon Jan 05, 3:40PM CST
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT)...
RPTP: 10.56 (-0.17), CNAT: 6.31 (-0.15), ICPT: 280.45 (-8.26), FGEN: 26.46 (-1.37)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 8.00 (-0.27), FGEN: 26.46 (-1.37), ABBV: 64.52 (+0.91), NVS: 103.45 (-0.62)
FibroGen: For One Of The More Promising Biotechs, A New Chance To Buy In
Don Dion - at Seeking Alpha - Tue Dec 09, 1:09PM CST
FGEN: 26.46 (-1.37)
What Are Your Stocks Really Worth?
Interactive Brokers - Seeking Alpha - Fri Dec 05, 3:00AM CST
The stock market by definition is the meeting place of willing buyers and sellers. But when you made a stock purchase, did you ever stop and think about who was on the other side of the trade? Chances are that a short seller provided liquidity rather...
KNDI: 12.22 (+0.11), INO: 10.39 (-0.09), GPRO: 46.25 (+1.94), GDP: 3.58 (-0.10), XONE: 14.83 (-0.14), CHKR: 8.14 (-0.07), LOCO: 28.22 (-0.34), FGEN: 26.46 (-1.37), DGLY: 13.13 (+0.08), PFL: 11.43 (+0.01)
FibroGen, Inc. Announces Full Exercise of Greenshoe Option
Business Wire - Mon Nov 17, 6:05AM CST
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that the underwriters of its initial public offering exercised in full their option to purchase an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price of $18.00 per share, less the underwriting discount. With this exercise, the initial public offering totals 9,315,000 shares of common stock of FibroGen, representing gross proceeds of approximately $167.7 million, prior to deducting the underwriting discount and estimated offering expenses.
FGEN: 26.46 (-1.37)
FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST
IPF: 22.43 (+0.06), AZN: 73.35 (+0.65), FGEN: 26.46 (-1.37)
IPO Preview: FibroGen
IPOdesktop - at Seeking Alpha - Fri Nov 14, 11:14AM CST
Based in San Francisco, CA, FibroGen (NASDAQ: FGEN ) scheduled a $124 million IPO on Nasdaq with a market capitalization of $975 million at a price range midpoint of $17.50 for Friday, Nov. 14, 2014. The full IPO calendar is available at ...
FGEN: 26.46 (-1.37)
FibroGen sets IPO price
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 6:45AM CST
FGEN: 26.46 (-1.37)
FibroGen, Inc. Announces Pricing of Its Initial Public Offering
Business Wire - Thu Nov 13, 8:56PM CST
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announces the pricing of its initial public offering of 8,100,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the shares are being offered by FibroGen. FibroGen completed a 1-for-2.5 reverse stock split effective as of November 10, 2014. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "FGEN" on November 14, 2014. In addition, FibroGen has granted the underwriters a 30-day option to purchase up to an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price. The offering is expected to close on November 19, 2014, subject to customary closing conditions.
FGEN: 26.46 (-1.37)
IPO Calendar: Virgin America Among 10 IPOs This Week
at Investor's Business Daily - Mon Nov 10, 3:32PM CST
Airline company Virgin America is among 10 IPOs scheduled this week that look to raise $2.2 billion, with half coming from the health care sector. The largest initial public offering planned is Axalta Coating Systems (AXTA), which looks to raise...
VA: 30.99 (+1.01), NAP: 15.15 (-0.26), AXTA: 30.99 (-0.57), EHIC: 10.38 (+0.08), FGEN: 26.46 (-1.37), PRAH: 27.90 (+0.42), SXB: (), LMRK: 17.77 (+0.15), JYNT: 8.56 (+0.31), NDRM: 13.35 (-0.74)
FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST
IPO: 24.98 (+0.05), BIS: 30.54 (+0.15), BIB: 177.06 (-0.89), AZN: 73.35 (+0.65), IBB: 363.84 (-0.66), FGEN: 26.46 (-1.37)
Week Ahead: 10 U.S. IPOs Planned For The Week Of November 10 As The IPO Market Hits 250 With Virgin America
Renaissance Capital IPO Research - Seeking Alpha - Mon Nov 10, 10:18AM CST
10 deals are on the IPO calendar for the week of November 10, 2014. The two largest, auto paint maker Axalta Coating Systems and contract research organization PRA Health Sciences, are both LBOs. Representing 27% of 2014 deal flow (65 to date),...
VA: 30.99 (+1.01), NAP: 15.15 (-0.26), AXTA: 30.99 (-0.57), EHIC: 10.38 (+0.08), FGEN: 26.46 (-1.37), PRAH: 27.90 (+0.42), SXB: (), LMRK: 17.77 (+0.15), JYNT: 8.56 (+0.31), NDRM: 13.35 (-0.74)
